Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Leukemia 1

Interventions

Cyclophosphamide 69fludarabine phosphate 66Peripheral Blood Stem Cell Transplantation 52Mycophenolic Acid 48Whole-Body Irradiation 47Tacrolimus 44Busulfan 43Cyclosporine 38Azacitidine 35Methotrexate 28Filgrastim 27Antilymphocyte Serum 27Cytarabine 26Decitabine 23Melphalan 22Radiotherapy 21fludarabine 20venetoclax 16Methylprednisolone 16Cyclosporins 13Cord Blood Stem Cell Transplantation 13Injections 12Granulocyte Colony-Stimulating Factor 12Flow Cytometry 12Specimen Handling 11Etoposide 11Biopsy 11Stem Cell Transplantation 10Sirolimus 10Clofarabine 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Leukemia, Myelomonocytic, Chronic × Amsacrine × Clear all
NCT05807932 2024-05-01

Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML

Heinrich-Heine University, Duesseldorf

Phase 1/2 Recruiting
38 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡